Evidence map›Paper›PMID 39420453›Full record

ArticlePsycho-oncology2024

Clinical Significance Unveiled: Understanding the Meaning of FACE-Q Skin Cancer Scores for Improved Patient Care.

Inge J Veldhuizen, Stephen W Dusza, Alyce Kuo, Abdullah Aleisa, Elliot Blue, Sushmita Adhikari, Umer Nadir, Kim Le, Soroush Kazemi, Adam V Sutton and 8 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Psycho-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Inge J VeldhuizenDermatology Division, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Stephen W DuszaDermatology Division, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Alyce KuoDermatology Division, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Abdullah AleisaDepartment of Dermatology, King Saud University, Riyadh, Saudi Arabia.
Elliot BlueDepartment of Dermatology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Sushmita AdhikariDepartment of Dermatology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Umer NadirDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Kim LeDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Soroush KazemiDepartment of Dermatology, UC Davis, David, California, USA.
Adam V SuttonDepartment of Dermatology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Rajiv I NijhawanDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Daniel B EisenDepartment of Dermatology, UC Davis, David, California, USA.
Anthony M RossiDermatology Division, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Divya SrivastavaDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Ashley WysongDepartment of Dermatology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Kishwer S NehalDermatology Division, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Anne F KlassenDepartment of Pediatrics, McMaster University, Hamilton, Canada.
Erica H LeeDermatology Division, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectiveThe FACE-Q Skin Cancer Module is a Patient-Reported Outcome Measure (PROM) utilized to assess outcomes following facial skin cancer resection. However, the lack of Minimal Important Difference (MID) estimates hinders the interpretability of the PROM scores. This study established MID estimates for the four outcome scales from the FACE-Q Skin Cancer Module using distribution-based methods.

methodsA prospective cohort study at four hospitals in the United States, enrolled participants who underwent Mohs Micrographic Surgery (MMS) for facial skin cancer between April 2020 and April 2022. Participants completed the Satisfaction with Facial Appearance, Appearance-related Psychosocial Distress, Cancer Worry, and Appraisal of Scars scales at four time points: pre-operatively, 2-week, 6-month, and 1-year post-surgery.

resultsA total of 990 patients participated in the study, with completion rates of 98.4% for the pre-operative assessment, 70.8% at 2 weeks, 59.3% at 6 months, and 60.4% at 1 year. MID estimates, calculated using 0.2 standard deviation and 0.2 standardized response mean, were determined for the four scales. The mean MID estimates, based on a Rasch transformed score ranging from 0 to 100, were 5 for the Appraisal of Scars scale and 4 for the remaining three scales.

conclusionThis multicenter study provides valuable MID estimates for the FACE-Q Skin Cancer Module, specifically for the MMS patient population, enabling clinicians and researchers to better interpret scores, determine appropriate sample sizes, and apply the findings in clinical care.

Indexed as

Mohs SurgeryPatient Reported Outcome MeasuresSkin NeoplasmsAdultAgedAged, 80 and overCicatrixClinical RelevanceFacial NeoplasmsFemaleHumansMaleMiddle AgedPatient SatisfactionProspective StudiesQuality of Lifeminimal important differenceMohs micrographic surgerypatient‐reported outcome

Identifiers

PMID39420453
PMCPMC11789771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.